← All trials
NCT06005688
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 18, 2023
- Primary completion
- Oct 11, 2023
- Completion date
- Nov 24, 2023
- First posted
- Aug 22, 2023
- Last posted
- Nov 22, 2023
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PfizerLead sponsor
- PfizerStudy director
- Arvinas IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.